Search | Clinical Trials Finder

Conditions: Nausea
Interventions: Acupressure bands, Expectancy-neutral handout, Expectancy-neutral MP3, Expectancy-enhancing handout, Expectancy-enhancing MP3; Device · Other · Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: Buffalo, New York • East Syracuse, New York • Rochester, New York

Conditions: Melanoma
Interventions: Palonosetron; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chemotherapy-Induced Nausea and Vomiting
Interventions: Netupitant and Palonosetron, Aprepitant, Palonosetron, Dexamethasone; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 11
States / cities: Muscle Shoals, Alabama • Burbank, California • Los Angeles, California + 8 more

Conditions: Postoperative Nausea and Vomiting
Interventions: TIVA NoNarc; Drug
Lead sponsor: Coastal Anesthesiology Consultants; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Saint Augustine, Florida

Conditions: Postoperative Ileus, Postoperative Nausea, Postoperative Complications, Postoperative Nausea and Vomiting, Postoperative Vomiting, Aspiration Vomitus
Interventions: Bedside gastric ultrasound; Diagnostic Test
Lead sponsor: Eric Schwenk; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Malignant Neoplasm
Interventions: Netupitant, Palonosetron Hydrochloride, Questionnaire Administration; Drug · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Drug-induced Nausea and Vomiting
Interventions: Ondansetron, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 319 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Nausea and Vomiting
Interventions: Prochlorperazine, Ondansetron; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific, Breast Cancer, Gastrointestinal Cancer, Disease (or Disorder); Gynecological, Prostate Cancer
Interventions: MR Therapy, Relaxing Music (RM) Therapy, Standard Symptom Management, Questionnaires; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2022
U.S. locations: 9
States / cities: Wichita, Kansas • Ann Arbor, Michigan • Grand Rapids, Michigan + 6 more

Conditions: Alopecia, Anxiety, Breast Carcinoma, Cognitive Side Effects of Cancer Therapy, Colorectal Carcinoma, Depression, Fatigue, Lung Carcinoma, Nausea and Vomiting, Pain, Psychological Impact of Cancer, Sleep Disorder, Weight Change
Interventions: Quality-of-Life Assessment, Yoga; Procedure
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2016
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Ovarian Cancer
Interventions: Aprepitant; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Postoperative Nausea and Vomiting
Interventions: APD421, Placebo; Drug
Lead sponsor: Acacia Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Miami, Florida • Durham, North Carolina • Winston-Salem, North Carolina + 1 more

Conditions: Postoperative Nausea and Vomiting
Interventions: Ondansetron, Vestipitant; Drug
Lead sponsor: Accenture; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 7
States / cities: Sheffield, Alabama • Phoenix, Arizona • Boynton Beach, Florida + 3 more

Conditions: Obesity
Interventions: Tradipitant, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 3
States / cities: Los Angeles, California • Rochester, Minnesota • New York, New York

Conditions: Nausea, Vomiting, Familial Dysautonomia
Interventions: Dronabinol, Placebo; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Olanzapine 5 MG, Placebo; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Nausea, Postoperative Nausea and Vomiting, Postdischarge Nausea and Vomiting, Postoperative Pain
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Nausea, Vomiting
Interventions: Activated Nometex Device, Unactivated Nometex Device; Device
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years to 100 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Pruritus, Nausea/Vomiting
Interventions: Ondansetron, Placebo Comparator; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 3 Years to 17 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Dysmenorrhea, Headache, Migraine, Fatigue, Nausea, Mood Disturbance
Interventions: Pure Femme Tablets; Drug
Lead sponsor: Pure Green; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Sterling Heights, Michigan

Conditions: Breast Cancer, Nausea, Vomiting
Interventions: granisetron transdermal system, fosaprepitant dimeglumine, laboratory biomarker analysis; Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Postoperative Nausea and Vomiting, Sex Hormone, Transgender
Interventions: Orchiectomy, Hysterectomy, Augmentation mammoplasty; Procedure
Lead sponsor: Riverside University Health System Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 7,348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Moreno Valley, California

Conditions: Neoplastic Conditions
Interventions: Augmented reality (AR); Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 7 Years to 17 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Postoperative Nausea and Vomiting, Bariatric Sleeve Gastrectomy
Interventions: Wearable Transcutaneous electrical Nerve Stimulation unit to mitigate postoperative nausea and vomiting (PONV) in the Bariatric Surgical Patient, A sham device that will mimic the active wearable device. It will look the same, and buzz but will not actually admit a low-leve electric current that would stimulate the nerves.; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Plainsboro, New Jersey

Search by objective public record fields.

Alternative Approaches for Nausea Control

Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting

A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

Effect of Intraoperative Anesthetic Management on Postoperative Nausea and Vomiting in Bariatric Surgery

Assessing Gastric Motility and Distention in Postoperative Gastrointestinal Surgery Using Bedside Gastric Ultrasound: Predicting Risk of Aspiration Pneumonia, Ileus, Return of Bowel Function

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline (SPARED) Trial

Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department

Mindfulness Relaxation Compared With Relaxing Music and Standard Symptom Management Education in Treating Patients Who Are Undergoing Chemotherapy For Newly Diagnosed Solid Tumors

Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer

Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer

Study of APD421 as PONV Treatment (Prior Prophylaxis)

A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

The Safety, Tolerability and Efficacy of Dronabinol, for the Treatment of Nausea and Vomiting in Familial Dysautonomia

Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants

Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)

Relief Band as an Adjunct to Antiemetic Therapy in Patients Who Receive Mod to Highly Emetogenic Chemotherapy

Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?

Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea

Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

Exogenous Sex Hormones and PONV

A Pilot Clinical Trial to Determine the Feasibility of Administering an Electronic Tool to Assess Postoperative pAin, Nausea, and Vomiting in English or Spanish-Speaking Pediatric Patients With Neoplastic Conditions.

Use of Transcutaneous Electrical Nerve Stimulation Device, Reletex Reliefband, With Current ERAS (Enhanced Recovery After Surgery) Protocol to Further Decrease Postoperative Nausea and Vomiting in the Bariatric Surgical Patient Within the First 24 Hours Postoperatively.